Completed
PHASE4
INTERVENTIONAL
NCT04727671
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This prospective, non-randomised, open-label, clinical trial is conducting on polycystic ovary syndrome (PCOS) subjects to compare the effects of two pituitary suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on clinical and embryological IVF/ICSI outcomes, and on the follicular fluid levels of Placental Growth Factor (PlGF); which is known for his pivotal role in the regulation of ovulation, embryo development, and implantation
Interventions
Name:
Triptorelin acetate
Type:
DRUG
Description:
0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
Name:
Cetrorelix
Type:
DRUG
Description:
0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
Name:
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Type:
DRUG
Description:
Dosage adjustment according to the ovarian response.
Name:
Human Chorionic Gonadotropin (hCG)
Type:
DRUG
Description:
Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
Primary Outcomes
Measure:
Follicular fluid Placental Growth Factor (PlGF) Concentrations:
TimeFrame:
Immediately after oocyte retrieval (35±2 hours after hCG administration)
Description:
Follicular fluid samples will be obtained on the day of oocyte retrieval, then they will be centrifuged to eliminate cellular elements and debris. After that, the supernatants will be frozen at -80 until assayed using an Elisa kit.
Trial Information
NCT ID
NCT04727671
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Damascus University
Last Updated
December 15, 2025